Testosterone Therapy

Introduction to Testosterone Therapy

Testosterone therapy is used to treat various conditions, with different formulations available, including testosterone cypionate and Sustanon, which have different pharmacokinetic profiles 1, 2
The American College of Physicians provides recommendations for the administration of testosterone formulations, including testosterone cypionate and Sustanon 1, 2

Regular monitoring of hematocrit/hemoglobin levels, PSA levels, liver function, and lipid profiles is essential for patients using testosterone cypionate or Sustanon, with more critical monitoring of hematocrit/hemoglobin levels for testosterone cypionate 2
Regular monitoring of hematocrit, estradiol, and PSA is recommended for patients using testosterone cypionate, particularly those with cardiovascular risk factors or sensitive to mood fluctuations 1, 2
Patients with pre-existing conditions that independently increase hematocrit (e.g., chronic obstructive pulmonary disease) face greater risk of complications from increased blood viscosity during testosterone therapy 2
Elderly patients are more vulnerable to complications from increased blood viscosity due to testosterone therapy 2
Testosterone therapy can cause headaches primarily through erythrocytosis (increased red blood cell production) and subsequent blood viscosity changes, which may lead to cerebrovascular complications, particularly in elderly patients 2

The BAT (Bipolar Androgen Therapy) approach using testosterone cypionate 400mg every 28 days has been studied in prostate cancer patients with interesting results for quality of life 3
Sustanon is a mixture of four testosterone esters (testosterone propionate, phenylpropionate, isocaproate, and decanoate) that provide both rapid onset and prolonged action, resulting in more stable testosterone levels throughout the treatment period 1
Testosterone cypionate has a half-life of approximately 8 days and is typically administered every 1-2 weeks, creating significant peaks and troughs in testosterone levels 1
The American College of Physicians recommends administering testosterone cypionate every 1-2 weeks, while Sustanon is often administered every 2-3 weeks due to its longer-acting esters 1
Sustanon has a more moderate effect on erythropoiesis due to steadier hormone levels, resulting in lower peak-to-trough ratio and less dramatic hematocrit elevation 1
Testosterone cypionate has a higher risk of cardiovascular side effects due to higher peak levels, and more significant impact on blood viscosity, potentially affecting cerebrovascular circulation 1

Regular monitoring of hematocrit/hemoglobin levels during testosterone therapy is recommended, with appropriate interventions if erythrocytosis develops, including dose reduction, temporary discontinuation of testosterone, therapeutic phlebotomy or blood donation, and switching from injectable to transdermal preparations 2
The risk of erythrocytosis varies by administration route: injectable testosterone (up to 44% of patients experience elevated hematocrit), transdermal patches (3-18% experience erythrocytosis), and testosterone gel (11-18% experience erythrocytosis, dose-dependent) 2
Higher doses of testosterone correlate with increased risk of erythrocytosis and subsequent headaches 2

Testosterone may have effects on amyloid β metabolism in the brain, influence brain-derived neurotrophic factor (BDNF) concentrations, impact antioxidant gene transcription and superoxide dismutase levels, and convert to estradiol, which has its own neurological effects 4
Testosterone can affect cerebral blood vessels through changes in vascular tone and reactivity, potential alterations in coronary and cerebral blood flow, and fluid retention, which may exacerbate headaches in susceptible individuals 2